By Christine A. Wu, Senior Research Analyst, LSN
Venture philanthropic foundations have deep expertise that is often overlooked. Each foundation has a specific, genuine mission towards a disease area that provides them enormous capacity to bring forward more than any entrepreneur can realize. Along with funding, venture philanthropic investors can provide patient access for underserved populations, specialize in assessing and tracking “positively impactful” technology in their particular field, and utilize their own relationships with traditional ventures in creative ways, among other initiatives.
New York City is home to a great number of life science foundations. LSN has dedicated the Venture Philanthropy panel to the following five incredible Foundations for the RESI New York City Conference on November 15th. Moderated by John Walter, CEO and President of Alliance for Cancer Gene Therapy, the audience will have an exclusive opportunity to hear from:
- Alyssa Reimer, Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research
- Michael Batten, Director, Strategic Partnerships, Juvenile Diabetes Research Foundation (JDRF) T1D Fund
- Ken LaMontagne, VP of Research, Therapy Acceleration Program, Leukemia & Lymphoma Society
- Andres Hurtado-Lorenzo, Director of Translational Research, Crohn’s and Colitis Foundation
Venture philanthropy investors maintain the genuine purpose of moving forward in the field of life science. Non-traditional investors such as these groups are great funding sources with incredible knowledge in their fields, while also taking inspirational strides to achieve their goals.
Foundations are a strong reminder not to lose track of the mission in life science.
Register before it’s too late to hear first-hand from this fantastic panel!
Leave a Reply